Eularis supports companies in forecasting future growth areas for the pharmaceutical industry by evaluating patient demand, new scientific discoveries, digital and AI-driven development, collaborations, and regulatory access pathways. The entire process of uncovering markets and competitive edges is undertaken with the goal of making the pharmaceutical industry more sustainable in terms of growth and profitability.
Beyond Failure Prevention: How AI is Redesigning the Drug Discovery Pipline
AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with Vitalay Fomin of Numenos about biomarker discovery, patient stratification, and why the next breakthroughs come from breaking down data silos across diseases, modalities, and even species.
Write a comment ...